Nuvation Bio Inc. (NUVB) FY2026 Q2 P&L / Income Statement

Nuvation Bio Inc. (NUVB) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Related Party Transaction. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

31,687,000 US dollars

Total costs and expenses

82,723,000 US dollars

Loss from operations

negative 51,036,000 US dollars

Total other (expense) income, net

negative 11,804,000 US dollars

Income (loss) before income taxes

negative 62,840,000 US dollars

Provision for income taxes

0 US dollars

Net loss

negative 62,840,000 US dollars

License

8,495,000 US dollars

Product Revenue - Innovent

4,400,000 US dollars

Research And Development Service Revenue - Innovent

2,000,000 US dollars

Royalty Revenue - Innovent

1,600,000 US dollars

Royalty Revenue - NK

500,000 US dollars

Undisclosed (calculated)

14,692,000 US dollars

Total costs and expenses

82,723,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.